21:05:25 Europe / Stockholm
Svenska | English

Mentice

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-07-23 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning MNTC 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-03 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-20 Kvartalsrapport 2023-Q2
2023-05-12 Ordinarie utdelning MNTC 0.00 SEK
2023-05-11 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-03 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-28 Ordinarie utdelning MNTC 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-03 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning MNTC 0.00 SEK
2021-05-06 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-04 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning MNTC 0.00 SEK
2020-05-27 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-08-28 Extra Bolagsstämma 2019

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Mentice är verksamt inom medicinteknik. Bolaget utvecklar medicinska instrument för endovaskulär simulering samt för träningstillfällen inom kirurgi. Programmen är utvecklade för att användas i utbildningssyfte bland sjukhus och institut. Störst verksamhet återfinns inom Nordamerika och Europa. Utöver huvudverksamheten erbjuds möjligheter till leasing, support, samt teknisk service. Huvudkontoret ligger i Göteborg.
Mentice publishes the company’s interim report for the period July – Sept 2023
2023-10-26 08:30:00

THIRD QUARTER WITH CONTINUED STRONG GROWTH, POSITIVE EBITDA AND IMPROVED CASHFLOW

SIGNIFICANT EVENTS DURING THE QUARTER 2023 (JUL – SEP) 

  • Mentice has appointed Henrik Hang as Interim CFO 
  • Mentice has appointed Jonathan Sjöström as the new COO. 
  • Mentice has received a significant order of approx. 0.6 MEUR from a major distributor in APAC. 


THIRD QUARTER 2023 (JUL - SEP) 

  • Order intake amounted to 65.3 (50,2) MSEK, an increase of 30.0%. 
  • Order book by the end of the period was 128.6 (113.9) MSEK, whereof 37.6 MSEK is expected as revenue in 2023. 
  • Net sales amounted to 63.9 (51.1) MSEK, an increase of 25.0%, whereof 19.3% is organic. 
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 4.0 (-1.9) MSEK. 
  • Net income for the period amounted to 0.0 (-7.7) MSEK. 
  • Earnings per share (EPS) were 0.0 (-0.30) SEK. 
  • Cash flow from operating activities amounted to 42.3 (-4.1) MSEK.


NINE MONTHS 2023 (JAN – SEP) 

  • Order intake amounted to 200.4 (161,9) MSEK, an increase of 23.7%. 
  • Order book by the end of the period was 128.6 (113.9) MSEK, whereof 39.7 MSEK is expected as revenue in 2023. 
  • Net sales amounted to 203.2 (149.3) MSEK, an increase of 36,1%, whereof 29.9% is organic. 
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 21.9 (-15.5) MSEK. 
  • Net income for the period amounted to 0.0 (-32.8) MSEK. 
  • Earnings per share (EPS) were 0.0 (-1.31) SEK. 
  • Cash flow from operating activities amounted to 44.8 (-11.1) MSEK. 


Webcast presentation of the interim report
Date: October 26, 2023
Time: 10:00 CEST

To register for the presentation, please visit https://investor.mentice.com/

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-10-26 08:30 CEST.

Image Attachments
Mentice Q3 2023 Interim Report En

Attachments
Mentice Q3 2023 Delårsrapport ENG

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden